Through this application, NIAID-sponsored clinical research at Emory University will be integrated into the Emory HIV/AIDS Clinical Trials Unit (EHCTU). The EHCTU will perform clinical research trials through prior agreement with the AIDS Clinical Trials Group (ACTG) and the Microbicides Trials Network (MTN). In addition, the EHCTU has the scientific expertise and appropriate patient populations to make important contributions to the HIV Vaccine Trials Network (HVTN), the HIV Prevention Trials Network (HPTM) and the INSIGHT network. Emory scientists currently make important scientific and leadership contributions to each of these networks. Emory University is located in Atlanta, a city at the epicenter of the evolving HIV epidemic in the United States. Of the 101 metropolitan areas with a population greater than 500,000, Atlanta ranked 7th for AIDS reporting in 2003. Atlanta accounts for 67% of Georgia's African-American AIDS cases, 75% of Hispanic cases, and 56% of minority female cases. Emory faculty provides care for about6,000 HIV-infected men and over 1,000 infected women. The EHCTU will consist of an administrative core and three clinical research sites. Jeffrey Lennox, M.D. will be the Principal Investigator for the EHCTU and for the ACTG at Emory. Carlos del Rio, M.D. will be the Principal Investigator for the HPTN trials. The Ponce de Leon Center, where over 4,000 HIV-infected adults are in care, will be the research site for the ACTG and HPTN. Francis Priddy, M.D. will be the Principal Investigator for the HVTN and MTN trials. These trials will be done at the Hope Clinic of the Emory Vaccine Center, one of the leading HIV vaccine and microbicides testing sites in the United States. David Rimland, M.D. will be the Principal Investigator for the INSIGHT trials. These trials will be performed at the Atlanta Veterans Administration Medical Center, which has the largest population of HIV-infected veterans in the country. Dr's Lennox, del Rio, Priddy and Rimland are all faculty in the Division of Infectious Diseases, have an excellent working relationship and a demonstrated record of collaborative clinical research accomplishments. ADMINISTRATIVE COMPONENT:

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-A (M1))
Program Officer
Pouliot, Eileen M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Latkin, Carl A; Van Tieu, Hong; Fields, Sheldon et al. (2017) Social Network Factors as Correlates and Predictors of High Depressive Symptoms Among Black Men Who Have Sex with Men in HPTN 061. AIDS Behav 21:1163-1170
Anderson, Albert M; Lennox, Jeffrey L; Mulligan, Mark M et al. (2017) Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. J Neurovirol 23:106-112
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Rolle, Charlotte-Paige; Rosenberg, Eli S; Siegler, Aaron J et al. (2017) Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM. J Acquir Immune Defic Syndr 76:250-258
Ofotokun, Ighovwerha; Titanji, Kehmia; Vunnava, Aswani et al. (2016) Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS 30:405-14
Ofotokun, Ighovwerha; Titanji, Kehmia; Lahiri, Cecile D et al. (2016) A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial. Clin Infect Dis 63:663-671

Showing the most recent 10 out of 81 publications